ATE163938T1 - Tetrazolderivate von gallebnsäuren, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel - Google Patents

Tetrazolderivate von gallebnsäuren, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel

Info

Publication number
ATE163938T1
ATE163938T1 AT94106848T AT94106848T ATE163938T1 AT E163938 T1 ATE163938 T1 AT E163938T1 AT 94106848 T AT94106848 T AT 94106848T AT 94106848 T AT94106848 T AT 94106848T AT E163938 T1 ATE163938 T1 AT E163938T1
Authority
AT
Austria
Prior art keywords
compounds
gallebic
acids
production
medicinal products
Prior art date
Application number
AT94106848T
Other languages
German (de)
English (en)
Inventor
Alfons Dr Enhsen
Heiner Dr Glombik
Werner Dr Dr Kramer
Guenter Dr Wess
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of ATE163938T1 publication Critical patent/ATE163938T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT94106848T 1993-05-08 1994-05-02 Tetrazolderivate von gallebnsäuren, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel ATE163938T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315368 1993-05-08

Publications (1)

Publication Number Publication Date
ATE163938T1 true ATE163938T1 (de) 1998-03-15

Family

ID=6487579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94106848T ATE163938T1 (de) 1993-05-08 1994-05-02 Tetrazolderivate von gallebnsäuren, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel

Country Status (19)

Country Link
US (1) US5466815A (OSRAM)
EP (1) EP0624596B1 (OSRAM)
JP (1) JP3476157B2 (OSRAM)
KR (1) KR100333149B1 (OSRAM)
AT (1) ATE163938T1 (OSRAM)
AU (1) AU666440B2 (OSRAM)
CA (1) CA2123048C (OSRAM)
CY (1) CY2119B1 (OSRAM)
CZ (1) CZ289515B6 (OSRAM)
DE (1) DE59405410D1 (OSRAM)
DK (1) DK0624596T3 (OSRAM)
ES (1) ES2115096T3 (OSRAM)
FI (1) FI942075A7 (OSRAM)
GR (1) GR3026496T3 (OSRAM)
HU (1) HU217439B (OSRAM)
IL (1) IL109581A (OSRAM)
NO (1) NO304795B1 (OSRAM)
NZ (1) NZ260469A (OSRAM)
TW (1) TW289757B (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289020B (OSRAM) * 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
WO2000066611A1 (en) 1999-04-30 2000-11-09 Arch Development Corporation Steroid derivatives
US7086134B2 (en) * 2000-08-07 2006-08-08 Shipley Company, L.L.C. Alignment apparatus and method for aligning stacked devices
JP2005508281A (ja) * 2001-02-08 2005-03-31 ザ ユニバーシティー オブ シカゴ ステロイド誘導体
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
WO2002090375A2 (en) * 2001-05-03 2002-11-14 The University Of Chicago Liver x receptor agonists
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
US6816317B2 (en) * 2002-01-31 2004-11-09 Lightel Technologies Inc. Collimator for ready fitting to an optical device with precise optical alignment without need for adjusting positions or angles to compensate for offsets or deviations during optical device assembly and method of making same
CA2482195A1 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
CA2572770A1 (en) 2004-07-08 2006-01-19 Novo-Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
US7960439B1 (en) 2006-06-12 2011-06-14 Iowa State University Research Foundation, Inc. Environmentally sensitive foldable oligomers
US8829213B2 (en) * 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
MX386489B (es) 2010-11-04 2025-03-19 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
SG11201703717SA (en) 2014-11-06 2017-06-29 Enanta Pharm Inc Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
MX2017006833A (es) 2014-11-26 2018-02-13 Enanta Pharm Inc Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RU2017130466A (ru) * 2015-02-11 2019-03-12 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
JP2018519246A (ja) * 2015-04-28 2018-07-19 ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド コール酸誘導体、及びその製造方法及び医薬用途
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
ES2918698T3 (es) 2016-11-29 2022-07-19 Enanta Pharm Inc Proceso para la preparación de derivados del ácido biliar de las sulfonilureas
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
CA3058754A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
JP7328207B2 (ja) 2017-08-09 2023-08-16 アルビレオ・アクチボラグ コレスチラミンペレット、経口コレスチラミン製剤、及びそれらの使用
ES2942443T3 (es) 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
PT3810581T (pt) 2018-06-20 2025-03-05 Albireo Ab Modificações cristalinas de odevixibat
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
CN113301901B (zh) * 2019-01-14 2022-09-09 北京轩义医药科技有限公司 四唑啉酮取代的类固醇及其用途
PL3921028T3 (pl) 2019-02-06 2023-02-13 Albireo Ab Związki benzotiadiazepinowe i ich zastosowanie jako modulatory kwasów żółciowych
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2020190358A1 (en) * 2019-03-19 2020-09-24 Siemens Healthcare Diagnostics Inc. Compositions, devices, and methods of mitigating lipoprotein interference in in vitro diagnostic assays for hydrophobic analytes
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
CN114761080B (zh) 2019-12-04 2024-07-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AR120683A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
TWI877262B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
TWI871392B (zh) 2019-12-04 2025-02-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del ácido biliar
EP4069247B1 (en) 2019-12-04 2025-03-26 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
IL293379B1 (en) 2019-12-04 2025-12-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4243831A1 (en) 2020-11-12 2023-09-20 Albireo AB Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Ａｓｂｔ阻害剤の皮下投与
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
KR20250022070A (ko) * 2022-06-09 2025-02-14 산동 루예 파마슈티칼 컴파니 리미티드 19-노르 c3,3-이치환된 c21-아자헤테로고리 치환 스테로이드 및 이의 사용 방법
US20240067617A1 (en) 2022-07-05 2024-02-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP2025539895A (ja) 2022-12-09 2025-12-09 アルビレオ・アクチボラグ 腎臓の疾患の治療におけるａｓｂｔ阻害剤
WO2025119319A1 (zh) * 2023-12-08 2025-06-12 山东绿叶制药有限公司 一种gabaa受体调节剂的晶型及其制备方法和应用
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
IL100240A (en) * 1990-12-06 1995-10-31 Hoechst Ag Bile acid derivatives process for their preparation and use of these compounds as pharmaceuticals

Also Published As

Publication number Publication date
HU217439B (hu) 2000-01-28
AU6194794A (en) 1994-11-10
EP0624596A2 (de) 1994-11-17
DK0624596T3 (da) 1998-10-07
CA2123048C (en) 2005-11-29
KR100333149B1 (ko) 2002-09-19
GR3026496T3 (en) 1998-07-31
CZ289515B6 (cs) 2002-02-13
IL109581A (en) 1998-03-10
NO941677D0 (no) 1994-05-06
TW289757B (OSRAM) 1996-11-01
NO941677L (no) 1994-11-09
FI942075A0 (fi) 1994-05-05
AU666440B2 (en) 1996-02-08
HU9401443D0 (en) 1994-08-29
JPH06329695A (ja) 1994-11-29
JP3476157B2 (ja) 2003-12-10
CA2123048A1 (en) 1994-11-09
FI942075L (fi) 1994-11-09
FI942075A7 (fi) 1994-11-09
CY2119B1 (en) 2002-04-26
NZ260469A (en) 1995-03-28
EP0624596A3 (de) 1995-06-07
EP0624596B1 (de) 1998-03-11
HUT67390A (en) 1995-04-28
US5466815A (en) 1995-11-14
DE59405410D1 (de) 1998-04-16
ES2115096T3 (es) 1998-06-16
NO304795B1 (no) 1999-02-15
CZ113594A3 (en) 1994-12-15
IL109581A0 (en) 1994-08-26

Similar Documents

Publication Publication Date Title
ATE163938T1 (de) Tetrazolderivate von gallebnsäuren, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel
ATE183191T1 (de) Monomere gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel
ATE169633T1 (de) Nor-gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel
ATE160783T1 (de) Gallensäurederivate, verfahren zu ihrer herstellung und verwendung dieser verbindungen als arzneimittel
ATE132496T1 (de) 3-desmethyl-mevalonsäurederivate, verfahren zu ihrer herstellung, pharmazeutische präparate auf basis dieser verbindungen, ihre verwendung sowie zwischenprodukte
ATE103267T1 (de) 7-substituierte derivate der 3,5-dihydroxyhept-6- insaeure, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte.
ATE140918T1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
ATE87916T1 (de) 3-desmethyl-4-fluor-mevalonsaeurederivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen, ihre verwendung und zwischenprodukte.
ATE123022T1 (de) Pyridin-2,4- und 2,5-dicarbonsäure-derivate, verfahren zu ihrer herstellung, verwendung derselben sowie arzneimittel auf basis dieser verbindungen.
ATE66209T1 (de) Dihydropyridinamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE100088T1 (de) Substituierte pyridin-2,4-dicarbonsaeure-derivate, verfahren zu ihrer herstellung, verwendung derselben sowie arzneimittel auf basis dieser verbindungen.
DE3770726D1 (de) Decahydrochinolinderivate, verfahren zu ihrer herstellung und zwischenprodukte davon, ihre verwendung als arzneimittel und ihre pharmazeutischen zusammensetzungen.
DE3678470D1 (de) Neue 3-pyridylmethylnaphthylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE113598T1 (de) Substituierte vinylcephalosporine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE112276T1 (de) Aryl-chinolyl-substituierte 1,4-dihydropyridin- dicarbonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE87002T1 (de) Substituierte 3-phenyl-7h-thiazolo(3,2 -b> (1,2,4>triazin-7-one, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte.
ATE139227T1 (de) Acylsulfonamido-und sulfonamidopyridin-2- carbonsäureester sowie ihre pyridin-n-oxide, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel
DE3862404D1 (de) Benzylaminoaryl-dihydropyridinelactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee